Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

PSMD3 orchestrates metabolic reprogramming and immunogenic cell death in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMu HaoYSYan SongKAKenneth C. Anderson

Discussion

Loading...

Member takes

Overview

Preclinical studies show that inhibiting PSMD3 reduces apoptosis and improves immune response in multiple myeloma, suggesting its therapeutic potential.

Key Points

  • This research aims to investigate the role of PSMD3 in multiple myeloma and its potential as a therapeutic target.
  • Utilized in vitro and in vivo models to study PSMD3 effects in multiple myeloma cells.
  • Employed siRNA-mediated knockdown and inducible knockout techniques to analyze cell viability and apoptosis.
  • Conducted proteomic analyses to assess metabolic and immunogenic changes upon PSMD3 depletion.
  • Targeting PSMD3 leads to increased apoptosis and cell cycle arrest in multiple myeloma cells.
  • PSMD3 knockdown enhances mitochondrial dysfunction and activates the cGAS-STING pathway.
  • Inhibition of PSMD3 significantly suppresses tumor growth in xenograft mouse models, indicating its therapeutic relevance.

Cite This Study

Hao et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e207https://doi.org/10.1182/blood-2025-3926
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma2026 · 4 citations
  2. 2Multi-omics analysis identifies neutrophil degranulation as a PSMD3-regulated pathway in FLT3-mutated AML2025
  3. 3DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma2025
  4. 4Abstract P19: Mitohormetic Regulation in Multiple Myeloma: Exploiting Mitochondrial Stress Responses for Therapeutic Gain2024
  5. 5Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma2025 · 1 citations